Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX1 | P51575 | 1/20 | 0.56 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.56 |
| ▸ | TUBB | P07437 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | POLA1 | P09884 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CDK1 | P06493 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27686204 | 0.89 | P2RX1 (0.54) | P2RX1TMPRSS4TUBBCYP1A2CYP2C19 | |
| SCHEMBL10305317 | 0.86 | DNMT3A (0.52) | CYP1A2CYP2C19HTTSMN1; SMN2CDK1 | |
| SCHEMBL23675446 | 0.82 | TUBB (0.72) | P2RX1TMPRSS4TUBBCYP1A2CYP2C19 | |
| SCHEMBL4019571 | 0.81 | TUBB (0.63) | P2RX1TMPRSS4TUBBHTTPOLA1 | |
| SCHEMBL26097052 | 0.80 | HPGD (0.63) | P2RX1TMPRSS4TUBBCYP1A2CYP2C19 | |
| SCHEMBL10305331 | 0.80 | ADRB1 (0.42) | P2RX1TMPRSS4MEN1KMT2AHTT | |
| SCHEMBL13812639 | 0.77 | P2RX1 (0.66) | P2RX1TMPRSS4TUBBCYP1A2CYP2C19 | |
| SCHEMBL13236587 | 0.77 | TUBB (0.75) | P2RX1TMPRSS4TUBBCYP1A2CYP2C19 | |
| SCHEMBL30100461 | 0.77 | TUBB (0.75) | P2RX1TMPRSS4TUBBCYP1A2CYP2C19 | |
| SCHEMBL4020932 | 0.77 | AKR1C3 (0.46) | CYP1A2CYP2C19MEN1KMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1756043-B1 | ORTHO SUBSTITUTED ARYL OR HETEROARYL AMIDE COMPOUNDS | RAQUALIA PHARMA INC (JP) | 2009-07-01 | — | — | EP | disclosed |
| US-20090036495-A1 | Combinations Comprising Alpha-2-Delta Ligands and Ep4 Receptor Antagonists | PFIZER, INC. | 2009-02-05 | — | — | US | disclosed |
| EP-1740211-A2 | COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS AND EP4 RECEPTOR ANTAGONISTS | Pfizer Products Incorporated (US) | 2007-01-10 | — | — | EP | disclosed |
| US-20050250818-A1 | Ortho substituted aryl or heteroaryl amide compounds | PFIZER INC | 2005-11-10 | — | — | US | disclosed |
| WO-2005102389-A2 | COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS AND EP4 RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2005-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250818-A1 | Ortho substituted aryl or heteroaryl amide compounds | OPRL1, PTGER1, OPRM1 | P2RX1 110/4885TMPRSS4 4748/4885TUBB 4203/4885 |
| US-20090036495-A1 | Combinations Comprising Alpha-2-Delta Ligands and Ep4 Receptor Antagonists | PTGER4, PTGER2, OPRL1 | P2RX1 37/4885TMPRSS4 632/4885TUBB 2267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.